MSB (ASX) Ann: Third Quarter Results Presentation

Originally posted by otherperspective ↑

Having just listened to the conference call , I would make the following comments :
1) As ecool2 has already alluded to, we were treated to a ringing endorsement from Dr Joanne Kurtzberg, Director of the Pediatric Blood and Marrow Transplant Programme at Duke University Medical Center . She stated without any hesitation that she would “definitely” use Remestemcel-L (after approval) as first line therapy for children after being unresponsive to steroids. As a physician she would only be likely to try Jakafi, if Remestemcel-L failed to get a response. Prof S I compared the public trial data showing that patients treated with grades C/D aGVHD Mesoblast achieved 89% response rate compared to 41-43% for Jakafi. Dr Kurtzberg then proceeded to mention that Remestemcel-L was also preferred because it did not suppress the immune system and there were no problems with toxicity.
2) If priority review is given by the FDA for Remestemcel-L , (which as an orphan drug is highly likely in my opinion), we should receive a decision on approval within 6 months of the final module being filed by Mesoblast. In my view we should hear the decision around the end of March/April 2020. Very encouraging that confirmatory trials for adult and chronic aGVHD will be pursued as soon as possible assuming a successful outcome. SI also added “other indications” to his slide for label extension opportunities in 2020...other than the EB opportunity, this is something I do not remember hearing before....
3) AT LAST THE GENIE IS OUT OF THE BAG... 85% of MACE events have already occurred in the 566 patient Revascor trial. S I referenced the fact that many of phase 3 clinical trial patients were now in their 3rd and 4th year post enrolment...so he notes that there is now “an increase in MACE rate and an accelerating rate accrual. He let slip right at the end the Revascor trial is likely to complete “sooner than we had anticipated...see how the next few months will go”.
By my estimation, a continuance of a typical j curve of mortality risk and hospitalisation plotted against the enrolled patient profiles leads me to conclude that the REVASCOR TRIAL WILL CONCLUDE IN ABOUT 9-11 weeks. This will not come as a surprise to anyone who has read my posts before. Just consider the ramifications of the last statement. Revascor is aimed at 15-20% out of 8m patients suffering with CHF market that has failed to respond to all other treatments. It also could be fast tracked to give unique support to those 5,000 patients who annually undergo LVAD implants. If you want to be prudent and risk a successful Revascor trial at say 30%, you would still get a share price many many multiples of what it is today. Expect some real interest to develop in the shares in the next 2 months !
4) Interesting that in CLBP, over 50% of the 404 enrolled patients in the Phase 3, 3 arm study have already completed their 24 month study. S.I. said that “further disclosure” from the Phase 2 results would be made available “in due course” but there would be no public interim read outs of the current trials. He did mention, however, that there have been no “adverse events to date during the trial”. With a 50% improvement in pain score and 15% improvement in function, set as the hurdle rates to be achieved from the phase 3 trials ( simi lar to outcomes achieved in phase 2 trials ) we will have to wait until April 2020 for the trial to conclude .

In summary, many slides were familiar to us all from previous presentations. Mesoblast is shifting to a commercial footing. R&D costs will fall as phase 3 trials reach their conclusion whilst manufacturing facilities will correspondingly rise to facilitate production.
We already knew that Remestemcel-L achieved vastly superior clinical results to Jakafi in clinical trials...but it was good to hear, from a world renowned expert on the subject of aGVHD, state that MSB should be “first line” after steroids. Looking at the valuation of Incyte we should be very pleased at the thought of label extensions being sought in 2020 to allow Mesoblast entry into the adult and chronic market for aGVHD.
Lastly, the Revascor trials which first started back in 2014 is probably less than 3 months away from reaching its targeted 540 Major Cardiac Events...you have been warned ! This is the key takeaway from todays presentation !!!

Expand

I have to agree with all this. I have been waiting for another trader driven dump to load up some more, but I think it is getting too risky to wait. There is the very real risk that we could see both results for Resavacor and a major partnership agreement announced together. I would not want to be short at this point.

No.	Vol.	Price($)
2	1130	$1.65

No.

Vol.

Price($)

1130

$1.65

Price($)	Vol.	No.
$1.65	60037	3

Price($)

Vol.

No.

$1.65

60037

No.	Vol.	Price($)
2	1130	1.645
2	25200	1.640
1	50014	1.635
1	613	1.630
2	12409	1.620

No.

Vol.

Price($)

1130

1.645

25200

1.640

50014

1.635

613

1.630

12409

1.620

Price($)	Vol.	No.
1.650	60037	3
1.655	31812	2
1.660	35900	6
1.665	16500	2
1.670	49734	7

Price($)

Vol.

No.

1.650

60037

1.655

31812

1.660

35900

1.665

16500

1.670

49734

(20min delay)
Last $1.65		Change 0.070(4.44%)		Mkt cap ! $2.101B

Open	High	Low	Value	Volume
$1.58	$1.65	$1.58	$7.205M	4.437M

Ann: Third Quarter Results Presentation, page-6

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Inside the depths of Panasqueira: A legacy carved in rock

Investors cautious as Trigg Minerals issues unusual trading halt

ASX Market Close: BHP shares rise with iron ore – but so does CBA

Thursday's HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback | July 10

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Third Quarter Results Presentation, page-6

Top Stories

Listen: HotCopper Wire Podcast 017 – RBA holds the toppings

Inside the depths of Panasqueira: A legacy carved in rock

Investors cautious as Trigg Minerals issues unusual trading halt

ASX Market Close: BHP shares rise with iron ore – but so does CBA

Thursday's HotCopper trends: Mystery Trigg halt, Neurizon FDA feedback | July 10

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News